Claims for Patent: 11,147,790

Summary for Patent: 11,147,790

Title:	Treatment of cutaneous disorders
Abstract:	Methods of treating one or more skin lesions using cantharidin as well as associated compositions, treatment regimens, kits, devices, and systems are provided. A method of treating a subject having one or more skin lesions may involve administering a composition comprising cantharidin to one or more skin lesions. The method may allow for the efficacious treatment of the skin lesion(s) with minimal or no adverse side effects (e.g., severe adverse side effects, permanent damage of the dermal tissue, scarring, excessive blistering of skin surrounding the lesion, elevated plasma cantharidin concentration, systemic exposure to cantharidin). The efficacy and/or safety of the treatment may be due, to certain features of the composition and/or prolonged exposure of the skin lesion(s) to cantharidin. The methods described herein may be used for a wide variety of cutaneous disorders, including skin disorders that primarily affect the epidermis of skin.
Inventor(s):	Howard Welgus, Matthew Gene Davidson, Jayson Michael Rieger
Assignee:	Verrica Pharmaceuticals Inc
Application Number:	US16/619,675
Patent Claims:	1. A composition comprising: cantharidin, wherein the composition comprises about 0.88 weight per weight percent of cantharidin; acetone, wherein the composition comprises about 60 weight per weight percent of acetone; ethanol, wherein the composition comprises about 31.5 weight per weight percent of ethanol; castor oil, wherein the composition comprises about 1.4 weight per weight percent of castor oil; nitrocellulose, wherein the composition comprises about 4.5 weight per weight percent of nitrocellulose; hydroxypropyl cellulose, wherein the composition comprises about 0.88 weight per weight percent of hydroxypropyl cellulose; and camphor, wherein the composition comprises about 0.92 weight per weight percent of camphor. 2. A method of treating a skin lesion caused by an infection with molluscum contagiosum comprising administering the composition of claim 1 to at least a portion of the skin lesion. 3. A single use applicator device comprising the composition of claim 1. 4. A method of treating a subject having warts comprising administering a composition of claim 1 to at least a portion of the warts. 5. A method of treating a subject having warts or a skin lesion caused by an infection with molluscum contagiosum, comprising: administering the composition of claim 1 to at least a portion of the warts or skin lesion; and allowing at least a portion of the composition to remain on the warts or skin lesion, wherein greater than or equal to about 10% of the cantharidin administered during the administering step penetrates into the warts or skin lesion. 6. The composition of claim 1, wherein the composition further comprises: denatonium benzoate, wherein the composition comprises about 0.006 weight per weight percent of denatonium benzoate; and/or gentian violet, wherein the composition comprises about 0.0005 weight per weight percent of gentian violet. 7. The composition of claim 6, wherein the composition consists essentially of: about 0.88 weight per weight percent of cantharidin; about 60 weight per weight percent of acetone; about 31.5 weight per weight percent of ethanol; about 1.4 weight per weight percent of castor oil; about 4.5 weight per weight percent of nitrocellulose; about 0.88 weight per weight percent of hydroxypropyl cellulose; about 0.92 weight per weight percent of camphor; about 0.006 weight per weight percent of denatonium benzoate; and about 0.0005 weight per weight percent of gentian violet. 8. The method of claim 2 further comprising allowing at least a portion of the composition to remain on the skin lesion for greater than about 12 hours and less than or equal to about 24 hours. 9. The method of claim 2 further comprising allowing at least a portion of the composition to remain on the skin lesion for greater than about 18 hours and less than or equal to about 24 hours. 10. The method of claim 2 further comprising allowing at least a portion of the composition to remain on the skin lesion for less than or equal to about 24 hours. 11. The method of claim 2 further comprising allowing at least a portion of the composition to remain on the skin lesion for approximately 24 hours. 12. The method of claim 8, wherein the plasma concentration of cantharidin in the subject is less than or equal to about 3.3 ng/ml after at least 12 hours after the administration step. 13. The method of claim 5, wherein greater than or equal to about 50% of the cantharidin administered penetrates into at least a portion of the warts or skin lesion. 14. The method of claim 5, wherein greater than or equal to about 90% of the cantharidin administered penetrates into at least a portion of the warts or skin lesion.